Melanie A Ford, OTD Occupational Therapist - Physical Rehabilitation Medicare: Medicare Enrolled Practice Location: 1214 N Bennett St, Silver City, NM 88061 Phone: 505-534-1280 Fax: 505-534-9734 |
Faith Varela Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3514 N Fowler Ave, Silver City, NM 88061 Phone: 575-388-3127 |
Mr. Keith Kelly Stanley, OT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 1268 E 32nd St, Silver City, NM 88061 Phone: 575-534-1919 Fax: 575-534-0135 |
Mrs. Lesley Jo Ping, OTR/L Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 208 Us-180 W, Silver City, NM 88061 Phone: 575-956-6370 |
Jedediah Cheston Rudd, M.S., O.T.R/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4134 N Blackhawk Rd, Silver City, NM 88061 Phone: 575-574-8212 |
Sherrie E. Lavelle Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2810 N Swan St, Silver City, NM 88061 Phone: 505-956-2000 Fax: 505-956-2055 |
Protherapy Inc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1214 N Bennett St, Silver City, NM 88061 Phone: 505-534-1280 |
Patricia Bernal Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2810 N Swan St, Silver City, NM 88061 Phone: 575-956-2043 Fax: 575-956-2055 |
News Archive
Scientists have assembled the most detailed chronology to date of the human brain's long, slow slide into full-blown Alzheimer's disease.
Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.
The ATS Research Program is pleased to announce that William Zhang, MD, of Weill Cornell Medical Center is the recipient of the 2020-2021 ATS/CSL Behring Research Award in Acute Respiratory Distress Syndrome.
The U.S. Food and Drug Administration today released a warning letter issued to Zhejiang Huahai Pharmaceutical Co. Ltd. (ZHP), in Linhai, Taizhou Zhejiang China, the manufacturer of the active pharmaceutical ingredient (API) found in valsartan that is the subject of an ongoing FDA investigation into probable cancer-causing impurities in certain commonly prescribed heart medicines.
And in this political climate, the $210 billion price tag [to fix the physician payment system] will probably prevent a permanent solution this year. However, a longer term, interim fix and a primary care payment differential would be steps in the right direction (Dennis Mayeaux and Lori Parham, 9/13).
› Verified 5 days ago